Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

Company Overview

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults. The company is also evaluating mitapivat and other investigational therapies for additional rare blood disorders, including sickle cell disease and thalassemia.

Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios initially developed a broad oncology pipeline based on cancer metabolism. It later transferred its oncology business to Servier, retaining certain rights and economic interests, and shifted its strategic focus toward rare diseases. Agios’ products and clinical programs are intended for patients in the United States and international markets, supported by regulatory and commercial partnerships where applicable. Brian Goff serves as the company’s chief executive officer.

Key Stats

• Today's Range: $33.32 to $34.28
• 50-Day Range: $30.02 to $44.01
• 52-Week Range: $22.24 to $46.00
• Volume: 750,165 shs
• Average Volume: 797,477 shs
• Market Capitalization: $2.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.25
• Consensus Rating: Moderate Buy

Agios Pharmaceuticals Stock Analysis - MarketRank™

Agios Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 358th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 1 strong buy rating, 5 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Agios Pharmaceuticals has a consensus price target of $41.25, representing about 22.8% upside from its current price of $33.60.

Amount of Analyst Coverage

Agios Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($5.82) to ($4.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agios Pharmaceuticals is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agios Pharmaceuticals is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Agios Pharmaceuticals has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.34% of the float of Agios Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Agios Pharmaceuticals has a short interest ratio ("days to cover") of 8.44.

Change versus previous month

Short interest in Agios Pharmaceuticals has recently decreased by 1.23%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agios Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Agios Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.48

News Sentiment

Agios Pharmaceuticals has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Agios Pharmaceuticals this week, compared to 9 articles on an average week.

MarketBeat Follows

1 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $914,400.00 in company stock.

Percentage Held by Insiders

5.40% of the stock of Agios Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Agios Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AGIO
• CIK: 1439222
• Web: www.agios.com
• Phone: (617) 649-8600
• Fax: N/A
• Employees: 540
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Agios Pharmaceuticals: $41.25
• High Price Target: $55.00
• Low Price Target: $32.00
• Potential Upside/Downside: +22.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.55
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$412.78 million
• Net Margins: -418.24%
• Pretax Margin: -419.27%
• Return on Equity: -35.67%
• Return on Assets: -33.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.22
• Quick Ratio: 9.79

Sales & Book Value

• Annual Sales: $54.03 million
• Price / Sales: 37.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $20.46 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 59,700,000
• Free Float: 56,478,000
• Market Cap: $2.01 billion
• Optionable: Optionable
• Beta: 0.60